Lawrence A Leiter Selected Research

Nateglinide (Starlix)

12/2013	Role of diuretics, β blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study.
3/2013	Predictors of incident heart failure hospitalizations among patients with impaired glucose tolerance: insight from the Nateglinide And Valsartan in Impaired Glucose Tolerance Outcomes Research study.
1/2012	Predictors of cardiovascular events in a contemporary population with impaired glucose tolerance: an observational analysis of the Nateglinide and Valsartan in impaired glucose tolerance outcomes research (NAVIGATOR) trial.
4/2010	Effect of nateglinide on the incidence of diabetes and cardiovascular events.
4/2010	Effect of valsartan on the incidence of diabetes and cardiovascular events.
9/2009	Role of renin-angiotensin system blockade in patients with diabetes mellitus.
1/2005	Of the renin-angiotensin system and reactive oxygen species Type 2 diabetes and angiotensin II inhibition.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Lawrence A Leiter Research Topics

Disease

153	Type 2 Diabetes Mellitus (MODY) 12/2022 - 09/2002
82	Cardiovascular Diseases (Cardiovascular Disease) 04/2022 - 01/2003
49	Myocardial Infarction 12/2022 - 01/2005
44	Heart Failure 01/2022 - 06/2005
32	Stroke (Strokes) 12/2022 - 01/2005
27	Coronary Artery Disease (Coronary Atherosclerosis) 12/2022 - 08/2002
26	Body Weight (Weight, Body) 01/2022 - 09/2002
22	Diabetes Mellitus 12/2022 - 01/2002
21	Hypoglycemia (Reactive Hypoglycemia) 03/2022 - 04/2010
21	Hypertension (High Blood Pressure) 12/2019 - 01/2005
20	Dyslipidemias (Dyslipidemia) 04/2022 - 06/2005
18	Coronary Disease (Coronary Heart Disease) 01/2020 - 07/2006
15	Hypercholesterolemia 05/2022 - 12/2002
14	Chronic Renal Insufficiency 12/2021 - 06/2005
14	Weight Loss (Weight Reduction) 01/2020 - 09/2010
13	Atherosclerosis 01/2021 - 01/2005
13	Acute Coronary Syndrome 09/2020 - 07/2003
12	Albuminuria 01/2021 - 06/2005
11	Ischemic Stroke 01/2022 - 11/2012
9	Infections 01/2021 - 01/2005
9	Unstable Angina 11/2020 - 01/2005
9	Cerebrovascular Disorders (Cerebrovascular Occlusion) 01/2018 - 05/2007
9	Glucose Intolerance 12/2013 - 01/2005
8	Hyperglycemia 03/2022 - 01/2005
8	Metabolic Syndrome (Dysmetabolic Syndrome X) 01/2020 - 01/2007
7	Hyperlipoproteinemia Type II (Familial Hypercholesterolemia) 04/2021 - 11/2019
7	Insulin Resistance 07/2020 - 01/2005
7	Isolated Systolic Hypertension 01/2017 - 06/2005
5	Obesity 01/2022 - 11/2010
5	Atrial Fibrillation 01/2022 - 01/2012
5	Prediabetic State (Prediabetes) 01/2022 - 12/2017
5	Diabetic Ketoacidosis (Ketoacidosis, Diabetic) 01/2021 - 01/2019
5	Inflammation (Inflammations) 01/2021 - 01/2005
5	Neoplasms (Cancer) 01/2020 - 07/2011
5	Urinary Tract Infections (Urinary Tract Infection) 11/2019 - 09/2013
5	Overweight 01/2019 - 02/2012

Drug/Important Bio-Agent (IBA)

56	Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA 05/2022 - 07/2003
44	Glucose (Dextrose)FDA LinkGeneric 03/2022 - 12/2004
44	LipidsIBA 01/2022 - 01/2002
31	LDL CholesterolIBA 01/2022 - 05/2005
29	CholesterolIBA 04/2022 - 12/2002
28	oxidized low density lipoproteinIBA 05/2022 - 01/2005
25	dapagliflozinIBA 01/2022 - 07/2014
24	Insulin (Novolin)FDA Link 10/2022 - 01/2005
18	Sodium-Glucose Transport ProteinsIBA 01/2022 - 09/2013
16	omega-Chloroacetophenone (Mace)IBA 01/2022 - 01/2018
15	Hypoglycemic Agents (Hypoglycemics)IBA 01/2021 - 06/2006
14	Glucagon-Like Peptide 1 (GLP 1)IBA 01/2022 - 11/2016
14	SodiumIBA 01/2021 - 05/2014
14	Atorvastatin (Lipitor)FDA Link 06/2013 - 01/2003
13	FructoseIBA 01/2020 - 02/2012
12	Sodium-Glucose Transporter 2 InhibitorsIBA 01/2022 - 09/2013
11	semaglutideIBA 01/2022 - 11/2016
11	Glucagon-Like Peptide-1 Receptor AgonistsIBA 01/2022 - 01/2016
10	Aspirin (Acetylsalicylic Acid)FDA LinkGeneric 12/2022 - 06/2005
10	Biomarkers (Surrogate Marker)IBA 11/2021 - 05/2007
10	Glucagon-Like Peptide-1 ReceptorIBA 11/2020 - 08/2014
10	Ezetimibe (Zetia)FDA Link 09/2020 - 01/2003
10	HDL CholesterolIBA 01/2020 - 01/2012
10	Blood Glucose (Blood Sugar)IBA 10/2018 - 09/2002
10	Angiotensin-Converting Enzyme Inhibitors (ACE Inhibitors)IBA 01/2018 - 06/2005
9	dulaglutideIBA 01/2022 - 01/2018
9	Liraglutide FDA Link 01/2022 - 01/2016
9	CreatinineIBA 01/2021 - 01/2012
9	Metformin (Glucophage)FDA LinkGeneric 01/2021 - 06/2006
8	empagliflozinIBA 01/2021 - 10/2019
8	Glycated Hemoglobin (Glycosylated Hemoglobin)IBA 01/2021 - 01/2008
8	alirocumabIBA 01/2020 - 01/2017
8	Angiotensin Receptor AntagonistsIBA 01/2018 - 06/2005
7	TicagrelorIBA 12/2022 - 05/2019
7	8- hydroxy- 2,2,14,14- tetramethylpentadecanedioic acidIBA 05/2022 - 10/2018
7	Insulin Glargine (Lantus)FDA Link 01/2022 - 10/2013
7	Proteins (Proteins, Gene)FDA Link 12/2021 - 01/2007
7	Rosuvastatin Calcium (Crestor)FDA Link 01/2021 - 10/2007
7	Pharmaceutical PreparationsIBA 01/2021 - 01/2018
7	AlbuminsIBA 01/2021 - 07/2011
7	Triglycerides (Triacylglycerol)IBA 07/2020 - 12/2010
7	Calcium Channel Blockers (Blockers, Calcium Channel)IBA 01/2016 - 06/2005
7	Nateglinide (Starlix)FDA LinkGeneric 12/2013 - 01/2005
7	Valsartan (Vals)FDA Link 12/2013 - 01/2005
7	1,4-dihydropyridine (dihydropyridine)IBA 07/2011 - 06/2005
6	saxagliptin FDA Link 11/2021 - 10/2013
6	IncretinsIBA 11/2020 - 02/2010
6	DiureticsIBA 01/2020 - 05/2007
6	SugarsIBA 01/2020 - 01/2014
6	CanagliflozinIBA 01/2018 - 09/2013
6	Peptidyl-Dipeptidase A (Angiotensin Converting Enzyme)IBA 07/2011 - 06/2005
6	ThiazidesIBA 05/2010 - 06/2005
5	insulin degludecIBA 01/2022 - 10/2013
5	candesartanIBA 01/2021 - 05/2016
5	Hydrochlorothiazide (Esidrix)FDA LinkGeneric 01/2021 - 05/2016
5	SymportersIBA 01/2021 - 04/2015
5	ALN-PCSIBA 01/2021 - 01/2017
5	Proprotein Convertase 9IBA 09/2020 - 01/2017
5	rGLP-1 proteinIBA 10/2018 - 08/2014

Therapy/Procedure

68	Therapeutics 04/2022 - 01/2003
26	Glycemic Control 01/2022 - 09/2002
7	Secondary Prevention 01/2021 - 12/2007
7	Subcutaneous Injections 01/2021 - 01/2017
5	Percutaneous Coronary Intervention 12/2022 - 12/2013